MX340403B - Composiciones apropiadas para la administracion oral, que comprenden un derivado de triazolo [4,5-d] pirimidina. - Google Patents

Composiciones apropiadas para la administracion oral, que comprenden un derivado de triazolo [4,5-d] pirimidina.

Info

Publication number
MX340403B
MX340403B MX2009001853A MX2009001853A MX340403B MX 340403 B MX340403 B MX 340403B MX 2009001853 A MX2009001853 A MX 2009001853A MX 2009001853 A MX2009001853 A MX 2009001853A MX 340403 B MX340403 B MX 340403B
Authority
MX
Mexico
Prior art keywords
triazolo
pyrimidin
compositions
derivate
oral administration
Prior art date
Application number
MX2009001853A
Other languages
English (en)
Other versions
MX2009001853A (es
Inventor
Banks Simon
Original Assignee
Aztrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39107049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340403(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aztrazeneca Ab filed Critical Aztrazeneca Ab
Publication of MX2009001853A publication Critical patent/MX2009001853A/es
Publication of MX340403B publication Critical patent/MX340403B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas y más particularmente a una composición farmacéutica que contiene {1S-[1a,2a,3ß(1S*,2R*),5ß]}-3-(7-{[2-(3,4-difluorofenil)cicloprop il]amino}-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il)-5 -(2-hidroxietoxi)ciclopentan-1,2-diol.
MX2009001853A 2006-08-21 2007-08-20 Composiciones apropiadas para la administracion oral, que comprenden un derivado de triazolo [4,5-d] pirimidina. MX340403B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82308306P 2006-08-21 2006-08-21
PCT/SE2007/000736 WO2008024045A1 (en) 2006-08-21 2007-08-20 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate

Publications (2)

Publication Number Publication Date
MX2009001853A MX2009001853A (es) 2009-03-02
MX340403B true MX340403B (es) 2016-07-07

Family

ID=39107049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001853A MX340403B (es) 2006-08-21 2007-08-20 Composiciones apropiadas para la administracion oral, que comprenden un derivado de triazolo [4,5-d] pirimidina.

Country Status (35)

Country Link
US (2) US8425934B2 (es)
EP (1) EP2056832B1 (es)
JP (2) JP5385139B2 (es)
KR (1) KR101539467B1 (es)
CN (1) CN101505754A (es)
AR (1) AR062451A1 (es)
AU (2) AU2007288541B9 (es)
BR (1) BRPI0715712B8 (es)
CA (1) CA2659328C (es)
CL (1) CL2007002421A1 (es)
CO (1) CO6150163A2 (es)
CY (1) CY1119380T1 (es)
DK (1) DK2056832T3 (es)
ES (1) ES2625930T3 (es)
HR (1) HRP20170694T1 (es)
HU (1) HUE031939T2 (es)
IL (2) IL196700A (es)
LT (1) LT2056832T (es)
MX (1) MX340403B (es)
MY (2) MY175009A (es)
NO (1) NO341787B1 (es)
NZ (2) NZ596700A (es)
PH (1) PH12013501627A1 (es)
PL (1) PL2056832T3 (es)
PT (1) PT2056832T (es)
RS (1) RS55884B1 (es)
RU (2) RU2476223C2 (es)
SA (1) SA07280442B1 (es)
SG (1) SG177162A1 (es)
SI (1) SI2056832T1 (es)
TW (1) TWI482772B (es)
UA (1) UA99105C2 (es)
UY (1) UY30551A1 (es)
WO (1) WO2008024045A1 (es)
ZA (1) ZA200900991B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CA2619402C (en) 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Method for producing betamimetics
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP3003276A1 (en) 2013-05-29 2016-04-13 ratiopharm GmbH Solid pharmaceutical dosage form
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104644604A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 替格瑞洛倍半水合物胶囊及其制备方法
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
CN104098520B (zh) * 2014-07-23 2016-01-20 张远强 苯基三唑希夫碱类化合物、其制备方法和用途
KR20160012706A (ko) * 2014-07-25 2016-02-03 동아에스티 주식회사 서방성 제제
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
EP3250207A1 (en) * 2015-01-27 2017-12-06 Astrazeneca AB Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
CN108883091A (zh) 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
CN105709230B (zh) * 2016-03-01 2019-05-31 北京鑫兰医药科技有限公司 一种替格瑞洛药物组合物及其制备方法
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
EA201892150A1 (ru) * 2016-04-21 2019-05-31 Астразенека Аб Распадающиеся в полости рта таблетки
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
TR201617983A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022035920A (ja) 2020-08-19 2022-03-04 アストラゼネカ・アクチエボラーグ 併用療法
BR102021011533A2 (pt) * 2021-06-14 2022-12-27 Libbs Farmacêutica Ltda Composição farmacêutica e uso da composição farmacêutica
WO2024089196A1 (en) 2022-10-28 2024-05-02 Astrazeneca Ab Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
CN1668282A (zh) * 2001-12-21 2005-09-14 辉瑞产品公司 可直接压制的阿齐霉素配方
PL373694A1 (en) 2002-02-15 2005-09-05 Teva Gyogyszergyar Reszvenytarsasag Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
US20040001885A1 (en) * 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
TW200418836A (en) 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
WO2004032905A1 (en) 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004037263A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Pharmaceutical compositions of ganciclovir
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
JP2005538038A (ja) * 2003-02-19 2005-12-15 テバ ジョジセルジャール レースベニュタールシャシャーグ 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
WO2005113006A2 (en) * 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
WO2006072878A1 (en) 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
MX2007009196A (es) * 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物

Also Published As

Publication number Publication date
UA99105C2 (ru) 2012-07-25
SG177162A1 (en) 2012-01-30
ZA200900991B (en) 2010-02-24
NO20090425L (no) 2009-03-05
RU2009104330A (ru) 2010-09-27
KR20090055561A (ko) 2009-06-02
US20080058353A1 (en) 2008-03-06
IL229130A0 (en) 2013-12-31
JP2010501554A (ja) 2010-01-21
NZ574514A (en) 2012-01-12
MY147966A (en) 2013-02-28
WO2008024045A1 (en) 2008-02-28
EP2056832A4 (en) 2012-12-26
RS55884B1 (sr) 2017-08-31
MX2009001853A (es) 2009-03-02
SA07280442B1 (ar) 2012-04-07
PH12013501627A1 (en) 2014-11-10
EP2056832A1 (en) 2009-05-13
DK2056832T3 (en) 2017-05-22
KR101539467B1 (ko) 2015-07-24
SI2056832T1 (sl) 2017-07-31
LT2056832T (lt) 2017-05-25
AU2007288541B9 (en) 2011-10-06
JP2014040448A (ja) 2014-03-06
US8425934B2 (en) 2013-04-23
PL2056832T3 (pl) 2017-09-29
EP2056832B1 (en) 2017-03-22
HUE031939T2 (en) 2017-08-28
CO6150163A2 (es) 2010-04-20
CY1119380T1 (el) 2018-02-14
AU2011205164A1 (en) 2011-08-25
RU2012153069A (ru) 2014-06-10
HRP20170694T1 (hr) 2017-07-28
AU2007288541A1 (en) 2008-02-28
BRPI0715712B8 (pt) 2021-05-25
BRPI0715712A2 (pt) 2014-06-24
NO341787B1 (no) 2018-01-22
RU2476223C2 (ru) 2013-02-27
CN101505754A (zh) 2009-08-12
NZ596700A (en) 2013-05-31
TWI482772B (zh) 2015-05-01
MY175009A (en) 2020-06-02
BRPI0715712B1 (pt) 2021-03-23
AU2007288541B2 (en) 2011-08-25
AU2011205164B2 (en) 2014-02-06
IL196700A0 (en) 2009-11-18
IL196700A (en) 2014-08-31
CL2007002421A1 (es) 2008-04-04
AR062451A1 (es) 2008-11-12
PT2056832T (pt) 2017-05-22
CA2659328A1 (en) 2008-02-28
JP5385139B2 (ja) 2014-01-08
UY30551A1 (es) 2008-03-31
CA2659328C (en) 2015-08-11
ES2625930T3 (es) 2017-07-21
US20130131087A1 (en) 2013-05-23
TW200817412A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
MX340403B (es) Composiciones apropiadas para la administracion oral, que comprenden un derivado de triazolo [4,5-d] pirimidina.
WO2008031556A3 (en) 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
UA101002C2 (ru) ПРОИЗВОДНЫЕ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
MX343702B (es) Proceso para preparacion de ciclopropilaminas opticamente activas.
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
SG156521A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
TN2011000245A1 (en) Organic compounds
EA201100032A1 (ru) Соединения пиридина
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
TW200800998A (en) Phenylalanine derivatives
TW200716568A (en) 1H-quinazoline-2,4-diones
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
TW200618801A (en) Pyrimidine derivatives
TN2009000362A1 (en) Weekly administration of dipeptidyl peptidase inhibitors
WO2004026836A3 (en) 1-pyridin-4-yl-urea derivatives
CA2562251A1 (en) Pyrazolo'4,3-d pyrimidines
CL2008003396A1 (es) (3ar,4s,6r,6as)-6-amino-2,2-dimetiltetrahidro-3ah-ciclopena[d][1,3]dioxol-4-ol dibenzoil-l-tartrato y su proceso de preparación.
WO2006044753A3 (en) Chemical compounds
HUP0303480A3 (en) 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, as crf-antagonists and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Grant or registration